A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors

This study has been terminated.
(Extreme toxicity of Pertuzumab and Erlotinib combination)
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Pamela L. Kunz, Stanford University
ClinicalTrials.gov Identifier:
NCT00947167
First received: July 23, 2009
Last updated: November 9, 2011
Last verified: November 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: May 2010
  Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)